According to a study, 42 individuals with a particular kind of rectal cancer who received experimental immunotherapy had a 100% positive response rate.
According to updated results this month, rectal cancer vanished in all patients included in a limited clinical trial of a novel immunotherapy treatment.
The pharmaceutical business GSK and the US-based Memorial Sloan Kettering Cancer Center (MSK) collaborated on the study.
It examined dostarlimab-gxly, a novel medication for the treatment of patients with a particular kind of rectal cancer brought on by a genetic mutation.
The study’s principal investigator, Dr. Andrea Cercek of MSK’s section head of colorectal cancer, said in a statement, “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.”
Mismatch repair deficient, or MMRd, indicates that a cell’s DNA repair system isn’t working properly. These comprise around 5% of all rectal cancer cases.
Currently, radiation, chemotherapy, surgery, or a mix of these are used to treat this type of cancer.
Medical oncologist Dr. Clélia Coutzac, who was not engaged in the study, states that intestinal issues, bowel incontinence, and sexual dysfunctions are only a few examples of how the therapies frequently negatively affect the patient’s quality of life.
Because dMMR tumors are hypermutated tumors, the immune system can recognize them clearly and will first attack and kill the cancer cells because it believes they are foreign. The immune system finally shuts down as the cancer progresses, Coutzac told Euronews Health.
“We reawaken the system with immunotherapy—in this example, GSK’s dostarlimab, a medication that will direct the lymphocytes to recognize the cancer cells as hazardous again and kill them—and it works extremely well in these tumors,” the speaker continued.
According to GSK, the patients who adhered to the six-month treatment plan demonstrated a full clinical response, with “no evidence of tumours” discovered by MRI, endoscopy, or digital exam during the follow-up.
Coutzac called the outcomes “amazing.”
More research is required before dostarlimab, also marketed under the brand name Jemperli, may be available on the market to treat MMRd rectal cancer.
The goal of the international research project Azur-1 is to validate the results of the MSK trial and investigate the effectiveness of dostarlimab-gxly when taken in isolation as opposed to chemotherapy, radiation therapy, or surgery.
